IL157841A0 - Activation of natural killer cells by adenosine a3 receptor agonists - Google Patents
Activation of natural killer cells by adenosine a3 receptor agonistsInfo
- Publication number
- IL157841A0 IL157841A0 IL15784102A IL15784102A IL157841A0 IL 157841 A0 IL157841 A0 IL 157841A0 IL 15784102 A IL15784102 A IL 15784102A IL 15784102 A IL15784102 A IL 15784102A IL 157841 A0 IL157841 A0 IL 157841A0
- Authority
- IL
- Israel
- Prior art keywords
- cells
- a3rag
- individual
- adenosine
- activation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/832,818 US20040204481A1 (en) | 2001-04-12 | 2001-04-12 | Activation of natural killer cells by adenosine A3 receptor agonists |
PCT/IL2002/000298 WO2002083152A1 (en) | 2001-04-12 | 2002-04-11 | Activation of natural killer cells by adenosine a3 receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL157841A0 true IL157841A0 (en) | 2004-03-28 |
Family
ID=25262686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15784102A IL157841A0 (en) | 2001-04-12 | 2002-04-11 | Activation of natural killer cells by adenosine a3 receptor agonists |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040204481A1 (xx) |
EP (1) | EP1383515B1 (xx) |
JP (1) | JP2004531523A (xx) |
AT (1) | ATE284698T1 (xx) |
DE (1) | DE60202278T2 (xx) |
IL (1) | IL157841A0 (xx) |
WO (1) | WO2002083152A1 (xx) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
AR049384A1 (es) * | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
WO2005117910A2 (en) | 2004-05-26 | 2005-12-15 | Inotek Pharmaceuticals Corporation | Purine derivatives as adenosine a1 receptor agonists and methods of use thereof |
US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
DK1778239T3 (da) * | 2004-07-28 | 2013-12-02 | Can Fite Biopharma Ltd | Adenosin-a3-receptor-agonister til behandling af sygdomme forbundet medtørre øjne, herunder sjögrens syndrom |
KR20070058626A (ko) | 2004-09-20 | 2007-06-08 | 이노텍 파마슈티컬스 코포레이션 | 퓨린 유도체 및 이것의 사용 방법 |
JP2008520747A (ja) * | 2004-11-22 | 2008-06-19 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | アデノシンa3受容体アゴニストを用いたhif−1が介在する疾患の促進的治療 |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
NZ568392A (en) | 2005-11-30 | 2011-07-29 | Inotek Pharmaceuticals Corp | Purine derivatives and methods of use thereof |
GB0625100D0 (en) * | 2006-12-15 | 2007-01-24 | Univ Murcia | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
US8883500B2 (en) | 2008-12-05 | 2014-11-11 | Northeastern University | Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy |
LT2523669T (lt) | 2010-01-11 | 2017-04-25 | Inotek Pharmaceuticals Corporation | Akispūdžio mažinimo būdas, derinys ir rinkinys |
WO2011119969A1 (en) | 2010-03-26 | 2011-09-29 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
DK2794627T3 (en) | 2011-12-22 | 2019-01-14 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES THEREOF |
RS56150B1 (sr) | 2012-01-26 | 2017-11-30 | Inotek Pharmaceuticals Corp | Anhidrovani polimorfi (2r,3s,4r,5r)-5-(6-(ciklopentilamino)-9h-purin-9-yl)-3,4-dihidroksitetrahidrofuran-2-yl)} metil-nitrata i postupak njegove pripreme |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
KR20150139501A (ko) | 2013-03-15 | 2015-12-11 | 이노텍 파마슈티컬스 코포레이션 | 안과용 제형 |
EP3844181A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
EP3843788A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
JP7449292B2 (ja) * | 2018-08-30 | 2024-03-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
EP3987010A1 (en) | 2019-06-21 | 2022-04-27 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL121272A (en) * | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
-
2001
- 2001-04-12 US US09/832,818 patent/US20040204481A1/en not_active Abandoned
-
2002
- 2002-04-11 DE DE60202278T patent/DE60202278T2/de not_active Expired - Fee Related
- 2002-04-11 IL IL15784102A patent/IL157841A0/xx unknown
- 2002-04-11 WO PCT/IL2002/000298 patent/WO2002083152A1/en active IP Right Grant
- 2002-04-11 JP JP2002580954A patent/JP2004531523A/ja not_active Withdrawn
- 2002-04-11 EP EP02726402A patent/EP1383515B1/en not_active Expired - Lifetime
- 2002-04-11 AT AT02726402T patent/ATE284698T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2002083152A1 (en) | 2002-10-24 |
JP2004531523A (ja) | 2004-10-14 |
EP1383515A1 (en) | 2004-01-28 |
EP1383515B1 (en) | 2004-12-15 |
ATE284698T1 (de) | 2005-01-15 |
DE60202278T2 (de) | 2005-12-15 |
DE60202278D1 (de) | 2005-01-20 |
US20040204481A1 (en) | 2004-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL157841A0 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
HUP0301405A2 (hu) | Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények | |
TW200501983A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
WO2005000215A3 (en) | Methods for treating pain | |
ATE418991T1 (de) | Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker | |
HK1097449A1 (en) | Methods for in vivo delivery of biologics and compositions useful therefor | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
EP3530288A3 (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
BR9406893A (pt) | Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids | |
HK1072541A1 (en) | Trans-epicutaneous administration form for treating restless leg syndrome | |
AU4258101A (en) | Combination therapies with vascular damaging activity | |
AR008799A1 (es) | Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento | |
AU8180001A (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells | |
DK1303278T3 (da) | Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme | |
CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
IL123642A (en) | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration | |
MXPA03001227A (es) | Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados. | |
AR036970A1 (es) | Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion | |
EP1185283A4 (en) | NEW THERAPEUTIC USE OF A VIRAL INJECTION MODULATING PROTEIN TO PREVENT EXHAUST FROM FOREIGN TRANSPLANTS | |
KR100403722B1 (en) | Lower alcohol insoluble extract of hovenia dulcis thunberg having liver protection activity, polysaccharide separated therefrom and composition containing the same | |
WO2001045714A3 (en) | Formulations of adenosine a1 agonists | |
FR2809725B1 (fr) | Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant | |
DE60008589D1 (de) | Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten | |
JPS6485990A (en) | Antihypertestoeronemia agent | |
WO2006000923A3 (en) | Macrolide compositions as therapeutic agent |